H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citing the company’s developments over its BEAM-302 therapy. This comes after Beam announced that it reached an agreement with the FDA on an expedited approval process for BEAM-302 in alpha-1 antitrypsin deficiency (AATD).

Pixabay/Public Domain

Beam Therapeutics Inc. (NASDAQ:BEAM) will take on about 50 more patients at the ideal biologic dose in its active Phase 1/2 trial in support of this filing. By the end of the first quarter of 2026, the company anticipates reporting new data and outlining the next phases for important development.

Beam Therapeutics Inc. (NASDAQ:BEAM) wrapped up 2025 with approximately $1.25 billion in cash, cash equivalents, and convertible securities, expanding its anticipated financial runway beyond 2029. This budget provides funds to carry out critical development of BEAM-302 and the planned risto-cel launch as the company moves into the commercial phase.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.

While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.